Kiromic BioPharma Inc (KRBP) Dividend History

$2.77 $-0.3

Dividend Score
Dividend Yield
0%

Annual Payment
$0

Payout Ratio
0%
Dividend Increases
0 yrs

Price Chart

Key Metrics

Sector Healthcare
Industry Biotechnology
Avg daily volume 0
Market cap 0
Beta 0.16
Trailing 12 Month EPS -13.35
Next Earnings Date
Ex-dividend date
P/E ratio 0

Company Description

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Dividend Payments

Forward Yield
0%
Forward Payment
$0

Trailing Yield
0%
Trailing Payment
$0

Last Increase
> 10 Years Ago
Last Cut
> 10 Years Ago

5 Year Average Yield
0%
Vs Current Yield
0%

5 Year Div Growth Rate
0%
Payment Frequency
-

Historical Dividend Payments